In contrast, 5 patients with BRCA1, BRCA2, and PALB2—all found in patients with tumor types not known to be associated with GPVs in these genes—did not have second hit and are unlikely to respond to PARP inhibitors.4 This evidence concerns the gene PALB2 and neoplasm.